Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection among Kidney Transplant Recipients: A Large Single-Center Experience
Table 4
Risk for all-cause mortality.
Covariate
Univariate analyses
Multivariate analyses
HR
95% CI
HR
95% CI
Age at COVID-19 diagnosis (per year)
1.07
1.06–1.09
<0.001
1.05
1.03–1.07
<0.001
Male recipient
1.57
1.12–2.19
0.009
1.26
0.89–1.78
0.19
Non-white recipient
1.76
1.24–2.48
0.001
1.46
1.01–2.12
0.04
Diabetes as a cause of ESKD vs other
2.54
1.84–3.50
<0.001
1.42
1.0–2.01
0.04
Living donor recipient
0.51
0.36–0.73
0.002
0.69
0.48–1.0
0.049
Previous transplant
0.65
0.42–1.01
0.06
1.06
0.66–1.69
0.80
Tacrolimus + MPA + prednisone maintenance vs other
1.04
0.75–1.45
0.79
Prednisone-based immunosuppression
2.80
1.38–5.72
0.004
1.45
0.69–3.06
0.96
Treatment of rejection before SARS-CoV-2 infection
0.45
0.1–1.79
0.26
Vaccinated
0.53
0.37–0.74
<0.001
0.52
0.37–0.74
0.003
Baseline eGFR (per mL/min/1.73 m2)
0.98
0.97–0.99
<0.001
0.98
0.97–1.0
0.01
Interval from transplant to COVID-19 (per month)
1.01
1.0–1.03
0.03
1.01
1.0–1.01
0.008
Hospitalization
19.18
11.7–32.7
<0.001
6.76
3.43–13.28
<0.001
Respiratory symptoms for hospital admission
11.31
7.5–16.5
<0.001
2.29
1.42–3.68
<0.001
Bold values signify statistically significant with p value less than 0.05.
